Author Archives: William Looney

Russian Innovation: A Higher Mark

The pursuit of excellence in biopharmaceutical innovation in Russia has never had a sponsor—until now. Prix Galien International, a global network of Nobel laureates in medicines, established its 18th country beachhead in Moscow earlier this year, culminating in a historic first: an October 24 awards dinner to recognize the best in new drug research as […]
Posted in E-Media, Events, R&D, Strategy | Tagged , , , , , , , , | Leave a comment

Nano Tech: Big Stakes in Small Things

Nano Tech: Big Stakes in Small Things New and emerging technologies are noteworthy not simply for the excellent science behind them but also for the way they expose those raw edges of the industry’s business model. In biopharma today, disruptive changes to the model are being driven by two forces. The first is advances in […]
Posted in Events, Regulatory, Technology | Tagged , , | Leave a comment

Typhoon Trauma: The Pharma Score on Disaster Relief

Big Pharma is quietly stepping up to provide critical supplies of essential medicines, other health equipment, and skilled local personnel to areas of the Philippines devastated by Typhoon Haiyan this month.  Although industry operations in the Philippines appear largely intact, most companies are working through global humanitarian aid organizations due to the logistical challenges created […]
Posted in Corporate Responsibility, Emerging Markets, Global | Tagged , , , , , , , | Leave a comment

Feds Take a Pass on Co-Pay Offsets Under Obamacare

Feds Take a Pass on Co-Pay Offsets Under Obamacare The implosion of the Affordable Care Act’s vaunted healthcare.gov benefit enrollment process has obscured a far more critical issue for big Pharma:  how much leeway do companies have in promoting durable brand affiliations among the potentially millions of new patients with subsidized access to new  medicines? […]
Posted in healthcare, Regulatory | Tagged , , , , , | Leave a comment

Putting a Price Tag on Compliance: Cheap Change or Big Bucks?

Compliance rules under the US Physician Payments Sunshine Act have been criticized for the excruciating level of detail demanded from individual company submissions.  But relatively little scrutiny has been accorded to another pressing question:  how much will all this new reporting cost?  The burden of compliance for not just this new law but in many […]
Posted in compliance, Marketing, Regulatory, Strategy | Tagged , , , , , | 1 Comment
  • Categories

  • Meta